Published on 21/12/2025

Essential Steps and Milestones in Initiating a Clinical Study

Launching a clinical trial is a complex process that involves multiple coordinated activities, regulatory interactions, and logistical milestones. In this tutorial-style article, we’ll explore the key milestones in clinical study start-up — from feasibility assessment to site initiation — that are critical for achieving timely and compliant trial activation.

Table of Contents

1. Protocol Finalization and Study Design Approval:

Before anything else, the clinical protocol must be developed and approved. This foundational document outlines the trial objectives, methodology, eligibility criteria, treatment plans, and data analysis strategy. Once finalized, it is submitted for internal scientific and ethical review.

Ensure alignment with ICH-GCP standards
Conduct scientific review with the sponsor or CRO
Obtain necessary protocol approval from senior medical teams

2. Feasibility Assessment and Site Selection:

Feasibility studies determine whether the proposed trial can be successfully conducted at the selected sites. This includes evaluating the patient population, infrastructure, investigator experience, and logistical capabilities.

Distribute and analyze site feasibility questionnaires
Engage with sites to assess recruitment potential
Select sites based on capability, experience, and timeline expectations

Robust feasibility reduces risks of startup delays and under-enrollment. Guidance and examples of such approaches can be found on StabilityStudies.in.

3. Budget and Clinical Trial Agreement (CTA) Negotiation:

Before any activities begin at site

level, budgeting and contractual arrangements must be finalized. This includes negotiation of trial-related costs and legal protections.

Draft and negotiate Clinical Trial Agreement with each site
Establish payment terms, indemnification, and insurance coverage
Ensure contracts are signed before site activation

4. Ethics and Regulatory Submissions:

Submitting the study to Institutional Review Boards (IRBs) or Ethics Committees (ECs) and regulatory bodies is a pivotal step in clinical trial start-up. These approvals are necessary before enrolling subjects.

Prepare IRB/EC submission packet
Submit Investigational New Drug (IND) application if applicable
Ensure compliance with USFDA or other regional regulatory guidelines

This step also includes preparing site-specific documentation and informed consent forms for approval.

5. Regulatory Document Collection and Site File Set-Up:

Each clinical trial site must maintain a Trial Master File (TMF) or Investigator Site File (ISF) containing regulatory documents. These are collected and reviewed before the site can be activated.

Signed protocol, CVs, medical licenses, and training certificates
EC/IRB approval letters and subject materials
Delegation logs, lab certifications, and study-specific SOPs

GMP principles should be followed for document control and archival, aligning with GMP documentation best practices.

6. Site Initiation Visit (SIV):

The SIV is conducted to train site personnel on the protocol, procedures, safety reporting, and data entry systems. It is a formal requirement before the site begins subject enrollment.

Schedule the SIV with the site’s principal investigator and staff
Review study objectives, timelines, safety protocols, and CRF/eCRF systems
Document training in site logs and confirm readiness for activation

7. Study Activation and Enrollment Start:

Once the SIV is complete and all documentation is in place, a site can be activated for subject enrollment. Study startup is deemed complete at this point.

Activate the site in CTMS and issue site activation letter
Start subject screening and informed consent process
Monitor initial enrollment progress and address site queries promptly

8. Typical Start-Up Timelines and Bottlenecks:

On average, clinical study start-up timelines range from 90–150 days depending on the complexity of the trial and country-specific regulatory environments. Bottlenecks may include:

Delayed ethics approval
Slow CTA negotiation
Feasibility feedback delays
Incomplete site documentation

Risk-based planning and early engagement of stakeholders are essential strategies to reduce startup cycle time.

9. Best Practices to Streamline Study Start-Up:

To ensure a smooth and compliant start-up process, follow these best practices:

Use a centralized start-up tracker to manage timelines
Conduct pre-submission readiness reviews
Implement SOPs for each start-up step (refer to Pharma SOPs)
Preload IRB/EC forms and country-specific submission templates
Communicate regularly with sites and CRO teams

10. The Role of Technology in Start-Up Management:

Modern clinical operations teams utilize digital tools to manage the complexity of start-up. These may include:

Study start-up management platforms
Electronic TMF (eTMF) systems
Contract management platforms for faster CTA workflows
Automated alert systems for milestone tracking

Integration with regulatory intelligence tools also helps anticipate region-specific hurdles and ensure compliance.

Conclusion:

Effective clinical study start-up is a critical determinant of trial success. By systematically managing milestones — from protocol approval through site initiation — clinical teams can mitigate delays, ensure compliance, and accelerate patient enrollment. Adopting best practices, leveraging digital tools, and following structured SOPs contribute to robust and predictable start-up outcomes.